Splenic marginal zone lymphoma with monoclonal IgG: A case report

Xupai Zhang,Shihui Ren,Nan Zhang,Xiao Wang,Lin Qiu,Haoping Sun,Hai Yi,Fangyi Fan

DOI: https://doi.org/10.1097/md.0000000000037158

IF: 1.6

2024-02-10

Medicine

Abstract:Splenic marginal zone lymphoma (SMZL) is an indolent small B-cell lymphoma originating from the splenic white pulp, which account for <2% of non-Hodgkin lymphoma. [ 1 ] Owing to the paucity of this disease entity, the feature of SMZL has only been characterized partly. The pathogenetic process is chronic and insidious and part of patients with SMZL even have no special clinical symptoms at diagnosis. Despite it originates from the spleen and the splenic hilar lymph nodes are susceptible to involve, peripheral blood and bone marrow are generally involved when confirming the diagnosis of SMZL. Subsequently, peripheral lymph nodes and extra-lymph node organs, liver for instance, can be infiltrated with the disease progressing. [ 2 ] Meanwhile, the patients with SMZL frequently combine with autoimmune disease such as autoimmune hemolytic anemia, Sjogren syndrome and immune thrombocytopenia. [ 3 ] In spite of its indolence, approximately 10% of individuals with SMZL probably convert into aggressive diffuse large B-cell lymphoma. [ 4 ] Furthermore, about one third of patients exist plasmocytic differentiation and secrete monoclonal paraproteins including IgM predominantly. Nevertheless, very few reports about the cases of SMZL with plasmocytic differentiation, especially accompanying with monoclonal IgG, are available at present. We currently report a case of SMZL with monoclonal IgG and meanwhile conduct literature review in order to improve the understanding of the diagnosis, differential diagnosis and treatment of this uncommon entity.

medicine, general & internal